Navigation Links
The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
Date:12/17/2009

PHOENIX, Dec. 17 /PRNewswire/ -- The Make-A-Wish Foundation announced today that it will receive a $1 million donation from the LATISSE® Wishes charitable public awareness campaign, sponsored by Allergan, Inc.

Based on the tradition of blowing on an eyelash to make a wish come true, the campaign launched earlier this year to raise awareness and support for the Make-A-Wish Foundation by leveraging the excitement around the availability of LATISSE® (bimatoprost ophthalmic solution) 0.03%, the first and only prescription treatment approved by the U.S. Food and Drug Administration for eyelash hypotrichosis (inadequate or not enough lashes) to grow lashes longer, fuller and darker.

With the $1 million contribution, the Make-A-Wish Foundation will be able to grant the wishes of more than 135 children with life-threatening medical conditions nationwide.

"The Make-A-Wish Foundation relies on contributions from programs such as the LATISSE® Wishes campaign to help us bring irreplaceable moments of joy to many deserving children," said David Williams, Make-A-Wish Foundation of America president and chief executive officer. "We strive to grant every eligible child's wish - and in fiscal year 2009, we were able to fulfill nearly 13,500 wishes, the most ever in the Foundation's history. This achievement is possible through the generosity of supporters such as Allergan and our donors, plus nearly 25,000 volunteers around the country."

The LATISSE® Wishes campaign launched with an initial donation of $500,000 from Allergan to the Make-A-Wish Foundation. To reach the $1 million goal, consumers around the country were encouraged to register by end of year on www.LATISSE.com. For every registration, Allergan pledged $5, up to an additional $500,000. Actress Brooke Shields and beauty expert to the stars Anastasia Soare, both LATISSE® users, served as ambassadors of the Make-A-Wish Foundation and LATISSE® Wishes campaign.

"Through my involvement with the Make-A-Wish Foundation and the LATISSE® Wishes campaign, I had the pleasure of meeting some amazing young people whose wishes have been granted by the Foundation," said Shields. "As a mother, it meant a lot to me to support such a meaningful organization, and I am thrilled that I could play a small role in making wishes come true for children facing life-threatening medical conditions."

"We're proud that the excitement around the launch of LATISSE® benefited such a worthy cause and grateful to the many consumers who helped increase our donation," said Robert Grant, president of Allergan Medical, a division of Allergan, Inc. "We look forward to ongoing collaboration between LATISSE® and the Make-A-Wish Foundation and strongly encourage others to consider the many different opportunities to support the Make-A-Wish Foundation in their communities."

The Make-A-Wish Foundation relies on the grassroots support of nearly 25,000 volunteers who serve its chapters in a variety of capacities, including wish granting, office administrative support, special event planning and coordinating, language translation, fundraising and much more. Through their efforts, the Make-A-Wish Foundation grants a wish every 40 minutes. For more information about the Make-A-Wish Foundation visit wish.org.

Important Information about LATISSE®

LATISSE® solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.

Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.

Important Safety Information

If you are using prescription products for lowering eye pressure or have a history of eye pressure problems, only use LATISSE® under close doctor supervision.

May cause eyelid skin darkening which may be reversible, and there is a potential for increased brown iris pigmentation which is likely to be permanent.

There is a potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces.

If you develop or experience any eye problems or have eye surgery, consult your doctor immediately about continued use of LATISSE®.

The most common side effects after using LATISSE® (bimatoprost ophthalmic solution) 0.03% are an itching sensation in the eyes and/or eye redness.

Full prescribing information is available at www.latisse.com and www.allergan.com.

About the Make-A-Wish Foundation

The Make-A-Wish Foundation grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Founded in 1980 when a group of caring volunteers helped a young boy fulfill his dream of becoming a police officer, the Foundation is now the largest wish-granting charity in the world, with 65 chapters in the United States and its territories. With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 185,000 wishes in the United States since its inception. For more information about the Make-A-Wish Foundation, visit wish.org and discover how you can share the power of a wish®.

About Allergan, Inc.

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential - to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

APC50FS09

Make-A-Wish Foundation, Make-A-Wish and share the power of a wish are the marks of the Make-A-Wish Foundation of America.

© 2009 Allergan, Inc. Irvine, CA 92612. ® marks owned by Allergan, Inc.

SOURCE Make-A-Wish Foundation


'/>"/>
SOURCE Make-A-Wish Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
2. CareCentrix Receives URAC Health Utilization Management Accreditation
3. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
4. SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System
5. Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets
6. EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution
7. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
8. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
9. Greenway Medical Technologies PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification
10. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
11. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5 2016 United Kingdom Ophthalmic ... GlobalData,s new report, "United Kingdom Ophthalmic Diagnostic ... data on the United Kingdom Ophthalmic Diagnostic Equipment ... US dollars, volume (in units) and average prices ... (OCT), Retinal Ultrasound Imaging Systems, Corneal Topography Systems, ...
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway ... now offering HIAC particle counting and sizing services for USP 788 and 789 ... the new service as a response to the needs of pharmaceutical and medical ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... focused on providing occupational safety and health training to public sector employees. , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... ... 05, 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to ... Over the course of three years, researchers will study concussions and changes in brain ... equipped with special sensors, will track the location and force of the hit. The ...
Breaking Medicine News(10 mins):